[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100461347":3},{"organization":4,"armGroups":7,"interventions":8,"overallOfficials":7,"centralContacts":19,"locations":28,"responsibleParty":48,"collaborators":7,"id":50,"slug":7,"hasResults":51,"nctId":52,"briefTitle":53,"officialTitle":53,"acronym":7,"eligibilityCriteria":54,"healthyVolunteers":51,"sex":55,"minAge":56,"maxAge":7,"enrollmentInfo":57,"targetDuration":7,"studyType":60,"phases":7,"briefSummary":61,"conditions":62,"keywords":64,"overallStatus":31,"whyStopped":7,"lastUpdateSubmitDate":70,"lastUpdatePostDateStruct":71,"startDateStruct":74,"completionDateStruct":76,"leadSponsor":78,"locationsCount":79},{"fullName":5,"class":6},"Hospital of Macerata","OTHER",null,[9],{"type":10,"name":11,"description":12,"armGroupLabels":7,"otherNames":13},"DRUG","pembrolizumab plus axitinib","collect global experiences with the use of immuno-combinations in patients with metastatic RCC",[14,15,16,17,18],"nivolumab plus cabozantinib","pembrolizumab plus lenvatinib","nivolumab plus ipilimumab","avelumab plus axitinib","atezolizumab plus bevacizumab",[20,25],{"name":21,"role":22,"phone":23,"phoneExt":7,"email":24},"Matteo Santoni, MD, PhD","CONTACT","+3907332572960","mattymo@alice.it",{"name":26,"role":22,"phone":7,"phoneExt":7,"email":27},"Giulia Sorgentoni, PhD","giulia.sorgentoni@libero.it",[29],{"facility":30,"status":31,"city":32,"state":33,"zip":34,"country":35,"cosmosGeoPoint":36,"geoPoint":41,"contacts":42},"Ospedale di Macerata, UOC Oncologia","RECRUITING","Province of Macerata","Macerata","62100","Italy",{"type":37,"coordinates":38},"Point",[39,40],13.45293,43.29789,{"lat":40,"lon":39},[43,44,46],{"name":21,"role":22,"phone":7,"phoneExt":7,"email":7},{"name":26,"role":22,"phone":45,"phoneExt":7,"email":27},"+3907332573752",{"name":21,"role":47,"phone":7,"phoneExt":7,"email":7},"PRINCIPAL_INVESTIGATOR",{"type":49,"investigatorFullName":7,"investigatorTitle":7,"investigatorAffiliation":7,"oldNameTitle":7,"oldOrganization":7},"SPONSOR","100461347",false,"NCT05287464","International Multicentric Study ARON-1","Inclusion Criteria:\n\n* Patients aged \\>18y\n* Cytological or Histologically confirmed diagnosis of clear cell or non-clear cell RCC\n* Histologically or radiologically confirmed diagnosis of metastatic disease\n* First-line treatment with nivolumab plus ipilimumab or nivolumab plus cabozantinib or pembrolizumab plus axitinib or pembrolizumab plus lenvatinib or avelumab plus axitinib or atezolizumab plus bevacizumab\n\nExclusion Criteria:\n\n* Patients without histologically confirmed diagnosis of RCC\n* Patients without histologically or radiologically confirmed metastatic disease\n* Patients treated with immuno-combinations not included in the list reported in the Inclusion Criteria Section","ALL","18 Years",{"count":58,"type":59},1220,"ESTIMATED","OBSERVATIONAL","The ARON-1 Study is designed as an International Multicentric Retrospective Study to collect global experiences with the use of immuno-combinations in patients with metastatic RCC.\n\nTwo Supplementary Studies (ARON-1α and ARON-1β) have been designed. The ARON-1α Supplementary Study has been designed to investigate for the presence of genomic signatures from tumor samples of patients treated with first-line immuno-combinations for advanced RCC. The ARON-1β Supplementary Study has been designed to charaterize the immune cell populations and assess their relationship with the clinical outcome of mRCC patients treated with first-line immuno-combinations",[63],"Metastatic Renal Cell Carcinoma (mRCC)",[65,66,67,68,69],"immunotherapy","mRCC","immuno-combinations","artificial intelligence technology","real-world data","2025-11-19",{"date":72,"type":73},"2025-11-26","ACTUAL",{"date":75,"type":73},"2022-03-10",{"date":77,"type":59},"2027-09-30",{"name":5,"class":6},1]